专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4412068A Novel compounds of the gentamicin class 失效
标题翻译：庆大霉素类的新型化合物
公开(公告)号：US4412068A
公开(公告)日：1983-10-25
申请号：US271552
申请日：1981-06-08
申请人： David Rosi
发明人： David Rosi
IPC分类号： C07H15/236 , C12P19/48 , C07G11/00 , C07H15/26 , C12R1/31
CPC分类号： C12R1/31 , C07H15/236 , C12P19/485 , Y02P20/55 , Y10S435/869
摘要： 5-Deoxygentamicin C.sub.2b and 6'-N-methyl-2-hydroxy- and 6'-N-methyl-5-deoxygentamicins C.sub.2b are prepared, as the major fermentation products, by culturing a nutrient medium containing carbohydrates, a source of assimilable nitrogen, essential salts and either D-streptamine or 2,5-dideoxystreptamine with a mutant of Micromonospora purpurea and isolating the fermentation products from the nutrient medium. The fermentation products are acylated with an ester of an .omega.-[N-(benzyloxycarbonyl)amino]-.alpha.-hydroxy-lower-alkanoic acid after first blocking the primary amino group at the 2'-position with an amine-protecting group, followed by catalytic hydrogenolysis of the benzyloxycarbonyl group and removal of the amine-protecting group to prepare the 1-(.omega.-amino-.alpha.-hydroxy-lower-alkanoyl) derivatives.
摘要翻译：通过培养含有碳水化合物的营养培养基，可同化氮源，制备5-脱氧虫酰胺Cbb和6'-N-甲基-2-羟基 - 和6'-N-甲基-5-脱氧阿霉素C2b作为主要的发酵产物，必需盐和D-链霉胺或具有小单孢菌突变体的2,5-二隐球菌素，并从营养培养基中分离发酵产物。在用胺保护基团首先封闭2位上的伯氨基后，将发酵产物用ω-[N-（苄氧基羰基）氨基]-α-羟基 - 低级 - 链烷酸的酯进行酰化，随后通过催化氢解苄氧羰基并除去胺保护基以制备1-（ω-氨基-α-羟基 - 低级烷酰基）衍生物。

2. 发明授权

US4365020A Method for the preparation of antibiotic sisomicin 失效
标题翻译：抗生素西索霉素的制备方法
公开(公告)号：US4365020A
公开(公告)日：1982-12-21
申请号：US214425
申请日：1980-12-08
申请人： Istvan Gado , Antonia Jekkel nee Bokany , Gyorgy Szvoboda , Miklos Jarai , Sandor Piukovich , Sandor Istvan
发明人： Istvan Gado , Antonia Jekkel nee Bokany , Gyorgy Szvoboda , Miklos Jarai , Sandor Piukovich , Sandor Istvan
IPC分类号： C12P19/54 , C12P1/04 , C12P19/48 , C12R1/29
CPC分类号： C12R1/29 , C12P19/485 , Y10S435/867
摘要： A process of producing sisomycin by cultivating a new species of Micromonospora.
摘要翻译：通过培育新型小单孢菌种生产西来霉素的方法。

3. 发明授权

US4234685A Microbiological methylation of aminoglycosyl-aminoglycosides 失效
标题翻译：氨基糖基 - 氨基糖苷类的微生物甲基化
公开(公告)号：US4234685A
公开(公告)日：1980-11-18
申请号：US51790
申请日：1979-06-25
申请人： Bong K. Lee , Gerald H. Wagman , Dinanath F. Rane , Joseph A. Marquez , Peter J. L. Daniels
发明人： Bong K. Lee , Gerald H. Wagman , Dinanath F. Rane , Joseph A. Marquez , Peter J. L. Daniels
IPC分类号： C12P19/48
CPC分类号： C12R1/29 , C12P19/485 , Y10S435/862 , Y10S435/867
摘要： The microorganisms Micromonospora inyoensis 1550F-1G and M. purpurea strain 1124 each microbiologically convert tobramycin, kanamycin A, kanamycin B and dibekacin to their respective 3"-N-methyl and 3"-N-methyl-4"-C-methyl derivatives. The derivatives exhibit significant activity against representative gram positive and gram negative bacteria and may also be converted to other derivatives which have significant antibacterial activity.
摘要翻译：微生物Micromonospora inyoensis 1550F-1G和M.peppurea菌株1124每个微生物转化妥布霉素，卡那霉素A，卡那霉素B和二卡西汀至其相应的3' - N-甲基和3“ - N-甲基-4'-C- 甲基衍生物。该衍生物对代表性的革兰氏阳性细菌和革兰氏阴性细菌表现出显着的活性，并且还可以转化为具有显着抗菌活性的其它衍生物。

4. 发明授权

US3499078A Everninomicin antibiotics and method for the manufacture thereof 失效
标题翻译：益生菌抗生素及其制备方法
公开(公告)号：US3499078A
公开(公告)日：1970-03-03
申请号：US3499078D
申请日：1968-09-25
申请人： SCHERING CORP
发明人： LUEDEMANN GEORGE M , WEINSTEIN MARVIN J
IPC分类号： A61K36/06 , C07H15/236 , C12P1/06 , C12P17/18 , C12P19/48 , A61K21/00 , C07G11/00 , C21D9/00
CPC分类号： C12R1/29 , C07H15/236 , C12P1/06 , C12P17/189 , C12P19/485 , Y10S435/863
摘要： Antibiotic No. 467 is produced by cultivating an antibiotic 467-producing strain of micromonospora halophytica var. nigra, especially NRRL 3097, or a 467-producing mutant thereof in an aqueous nutrient medium containing assimilable sources of carbon and nitrogen under aerobic conditions. Antibiotic No. 467 is found mainly in the clarified broth, from which it may be extracted at pH 2 to 9.5 with a water-immiscible organic solvent, e.g. ethylacetate. The solvent extract is concentrated and the antibiotic precipitated by a non-solvent such as hexane. Antibiotic 467 is insoluble in water, hexane and petroleum ether; soluble in ethyl acetate, methanol, butanol, benzene and ether; it is stable to acid and heat; contains C 60.73%, H 7.53%, N 3.70%, O 27.20%, Cl 0.04% and S 0.80%; U.V. 264 mm E1%=183 and 302 mm E1%=116 (inflection points); I.F. (Fig. 1); negative Ninhydrin and Sakaguchi tests; positive ferricyanide and reducing sugars; Rf values for various systems are specified; active against a wide range of gram-positive organisms. Paper chromatograms indicate the presence of various components of antibiotic No. 467. Therapeutic compositions comprise antibiotic No. 467, or a component thereof, and a carrier.
摘要翻译：抗生素号467是通过培养产生抗生素467的小孢子虫菌株变种产生的。黑质，特别是NRRL 3097，或其在含有营养培养基中的467产生突变体，其在需氧条件下含有可同化的碳和氮源。抗生素号467主要存在于澄清的肉汤中，可以用pH与水不混溶的有机溶剂例如pH 2至9.5进行萃取。乙酸乙酯。浓缩溶剂提取物，用非溶剂如己烷沉淀抗生素。抗生素467不溶于水，己烷和石油醚; 溶于乙酸乙酯，甲醇，丁醇，苯和乙醚; 对酸和热是稳定的; 含C 60.73％，H 7.53％，N 3.70％，O 27.20％，Cl 0.04％和S 0.80％; U.V. 264毫米E1％= 183和302毫米E1％= 116（拐点）; 如果。（图。1）; 负Ninhydrin和Sakaguchi测试; 正铁氰化物和还原糖; 指定各种系统的Rf值; 活跃于广泛的革兰氏阳性生物。纸张色谱图表明抗生素编号467的各种组分的存在。治疗组合物包含抗生素No.467或其组分和载体。

5. 发明公开

US20240301461A1 Recombinant Escherichia Coli for Expressing Synthesis Pathway of Asiaticoside and Application Thereof 审中-公开
公开(公告)号：US20240301461A1
公开(公告)日：2024-09-12
申请号：US18414523
申请日：2024-01-17
申请人： Jiangnan University
发明人： Jingwen Zhou , Weizhu Zeng , Xingying Zhao , Sha Xu , Jian Chen
IPC分类号： C12P19/48 , C12N1/20 , C12N9/10 , C12R1/19
CPC分类号： C12P19/485 , C12N1/205 , C12N9/1051 , C12N2527/00 , C12R2001/19
摘要： The present disclosure discloses recombinant Escherichia coli for expressing a synthesis pathway of asiaticoside and application thereof, and belongs to the field of bioengineering. Rhamnosyltransferase with an amino acid sequence shown in any one of SEQ ID NO: 25 to SEQ ID NO: 29, glucosyltransferase with an amino acid sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 17 and UGT73AH1 reported in a document are transferred into E. coli BL21 (DE3)Δpgi to realize co-expression. Fermentation results show that all 5 rhamnosyltransferases screened in the present disclosure can achieve effects, and a unique new peak appears at 0.596 min, which is consistent with a characteristic ion flow of an asiaticoside standard product. According to the present disclosure, barriers of the prior art are broken through, a new biosynthesis method for asiaticoside is provided, and industrialization of biosynthesis of asiaticoside becomes possible.

6. 发明申请

US20160331708A1 MEANS AND METHODS FOR INCREASING ANTIBIOTIC ACTIVITY 审中-公开
标题翻译：增加抗生素活性的手段和方法
公开(公告)号：US20160331708A1
公开(公告)日：2016-11-17
申请号：US15110936
申请日：2015-01-09
申请人： UNIVERSITEIT LEIDEN
发明人： Hye Kyong Kim , Anne van der Meij , Robert Verpoorte , Young Hae Choi , Gilles Philippus van Wezel
IPC分类号： A61K31/196 , A61K31/7036 , A61K31/165 , A61K31/7056 , A61K31/43 , A61K31/545 , A61K38/14 , A61K38/08 , A61K31/496 , C12P19/54 , C12P19/52 , C12P19/48 , C12P13/02 , C12P37/00 , A61K35/74
CPC分类号： A61K31/196 , A61K31/00 , A61K31/165 , A61K31/43 , A61K31/496 , A61K31/545 , A61K31/7036 , A61K31/7056 , A61K35/74 , A61K38/08 , A61K38/14 , C12P13/02 , C12P19/485 , C12P19/52 , C12P19/54 , C12P37/00 , A61K2300/00
摘要： The disclosure provides means and methods for increasing the activity of antibiotics. This enables the use of lower antibiotic dosages and the treatment of multidrug-resistant bacteria.
摘要翻译：本公开提供了增加抗生素活性的方法和方法。这使得能够使用较低的抗生素剂量和多药耐药性细菌的治疗。

7. 发明申请

US20130096078A1 NEW KANAMYCIN COMPOUND, KANAMYCIN-PRODUCING STREPTOMYCES SPECIES BACTERIUM, AND METHOD OF PRODUCING KANAMYCIN 有权
标题翻译：新的卡那霉素化合物，卡那霉素生产型菌体细菌和生产卡那霉素的方法
公开(公告)号：US20130096078A1
公开(公告)日：2013-04-18
申请号：US13642842
申请日：2010-10-14
申请人： Yeo Joon Yoon , Sung Ryeol Park , Je Won Park , Jae Kyung Sohng
发明人： Yeo Joon Yoon , Sung Ryeol Park , Je Won Park , Jae Kyung Sohng
IPC分类号： C12P19/48
CPC分类号： C12P19/485 , A61K31/351 , A61K31/7036 , C07H15/22 , C07H15/234 , C12N15/52 , C12N15/76 , C12R1/61 , Y02A50/473
摘要： Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.
摘要翻译：提供了表达kanA-kanB-kanK和其他卡那霉素生产相关基因的载体，用载体转化的链霉菌属重组细菌，细菌产生卡那霉素抗生素的方法和由细菌产生的新的卡那霉素化合物。通过使用本发明的重组细菌，可以直接发酵生物合成作为半合成的卡那霉素的阿米卡星和妥布霉素作为半合成卡那霉素的前体的卡那霉素B的产率。

8. 发明授权

US4348516A Microbiological methylation of aminoglycosyl-aminoglycosides 失效
标题翻译：氨基糖基 - 氨基糖苷类的微生物甲基化
公开(公告)号：US4348516A
公开(公告)日：1982-09-07
申请号：US158850
申请日：1980-06-12
申请人： Bong K. Lee , Gerald H. Wagman , Dinanath F. Rane , Joseph A. Marquez , Peter J. L. Daniels
发明人： Bong K. Lee , Gerald H. Wagman , Dinanath F. Rane , Joseph A. Marquez , Peter J. L. Daniels
IPC分类号： C12P19/48 , A61K31/71 , C07H15/22
CPC分类号： C12R1/29 , C12P19/485
摘要： The microorganisms Micromonospora inyoensis 1550F-1G and M. purpurea strain 1124 each microbiologically convert tobramycin, kanamycin A, kanamycin B and dibekacin to their respective 3"-N-methyl and 3"-N-methyl-4"-C-methyl derivatives. The derivatives exhibit significant activity against representative gram positive and gram negative bacteria and may also be converted to other derivatives which have significant antibacterial activity.
摘要翻译：微生物Micromonospora inyoensis 1550F-1G和M.peppurea菌株1124每个微生物转化妥布霉素，卡那霉素A，卡那霉素B和二卡西汀至其相应的3' - N-甲基和3“ - N-甲基-4'-C- 甲基衍生物。该衍生物对代表性的革兰氏阳性细菌和革兰氏阴性细菌表现出显着的活性，并且还可以转化为具有显着抗菌活性的其它衍生物。

9. 发明授权

US4387219A 2-Hydroxy gentamicin compounds 失效
标题翻译： 2-羟基庆大霉素化合物
公开(公告)号：US4387219A
公开(公告)日：1983-06-07
申请号：US209412
申请日：1980-11-24
申请人： Haruo Yamamoto , Sol J. Daum
发明人： Haruo Yamamoto , Sol J. Daum
IPC分类号： C07H15/236 , C12P19/48 , C07H15/22
CPC分类号： C12R1/31 , C07H15/236 , C12P19/485 , Y02P20/55
摘要： 2-Hydroxygentamicins B, B.sub.1 and A.sub.3 and 2-hydroxy antibiotics JI-20A and JI-20B are prepared as fermentation products by culturing a nutrient medium containing carbohydrates, a source of assimilable nitrogen, essential salts and D-streptamine with a mutant of Micromonospora purpurea, and isolating the said fermentation products from the nutrient medium; the fermentation products are acylated with an ester of an .omega.-(N-benzyloxycarbonyl)amino-.alpha.-hydroxy-lower-alkanoic acid, after first blocking the 6'-and/or 2'-amine group with an amine-protecting group, followed by catalytic hydrogenolysis of the benzyloxycarbonyl group and removal of the amine-protecting groups to prepare the 1-N-(.omega.-amino-.alpha.-hydroxy-lower-alkanoyl) derivatives.
摘要翻译：通过培养含有碳水化合物，可同化氮源，必需盐和D-链霉素的营养培养基，制备2-羟基阿霉素B，B1和A3和2-羟基抗生素JI-20A和JI-20B作为发酵产物，其具有小单孢菌突变体紫外线，并从所述营养培养基中分离所述发酵产物; 在用胺保护基团首先封闭6'-和/或2'-胺基团之后，用ω-（N-苄氧基羰基）氨基-α-羟基 - 低级 - 链烷酸的酯将发酵产物酰化，然后催化氢解苄氧羰基并除去胺保护基以制备1-N-（ω-氨基-α-羟基 - 低级烷酰基）衍生物。

10. 发明授权

US4275155A Manufacture of aminoglycoside antibiotics 失效
标题翻译：制造氨基糖苷类抗生素
公开(公告)号：US4275155A
公开(公告)日：1981-06-23
申请号：US67528
申请日：1979-08-16
申请人： Artur Pereira Da Luz
发明人： Artur Pereira Da Luz
IPC分类号： C07H15/234 , C12P19/48
CPC分类号： C07H15/234 , C12P19/485 , C12R1/29 , Y10S435/867
摘要： A process for the production of gentamicins or more specifically a mixture of gentamicins C.sub.1, C.sub.2 and C.sub.1 a by the aerobic fermentation of a new species Micromonospora scalabitana closely related to Micromonospora narashinoensis in suitable medium containing assimilable sources of carbon and nitrogen, calcium carbonate and several trace elements.
摘要翻译：一种生物庆大霉素或更具体地是庆大霉素C1，C2和C1a的混合物的方法，其通过需氧发酵新型物种小单孢菌属（Micromonospora scalabitana），与适当的含有碳和氮的碳源和几种痕迹的合适培养基中的微型单孢菌密切相关元素。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式